Nicotine Replacement Therapy for Smokers with Acute Aneurysmal Subarachnoid Hemorrhage: An International Survey.

Details

Ressource 1Download: s12325-022-02300-4.pdf (1075.62 [Ko])
State: Public
Version: Final published version
License: CC BY-NC 4.0
Serval ID
serval:BIB_65D8524DE1E9
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Nicotine Replacement Therapy for Smokers with Acute Aneurysmal Subarachnoid Hemorrhage: An International Survey.
Journal
Advances in therapy
Author(s)
Eisenring C.V., Hamilton P.L., Herzog P., Oertel M.F., Jacot-Sadowski I., Burn F., Cornuz J., Schatlo B., Nanchen D.
ISSN
1865-8652 (Electronic)
ISSN-L
0741-238X
Publication state
Published
Issued date
11/2022
Peer-reviewed
Oui
Volume
39
Number
11
Pages
5244-5258
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Smoking prevalence is twice as high among patients admitted to hospital because of the acute condition of aneurysmal subarachnoid hemorrhage (aSAH) as in the general population. Smoking cessation may improve the prognosis of aSAH, but nicotine replacement therapy (NRT) administered at the time of aSAH remains controversial because of potential adverse effects such as cerebral vasospasm. We investigated the international practice of NRT use for aSAH among neurosurgeons.
The online SurveyMonkey software was used to administer a 15-question, 5-min online questionnaire. An invitation link was sent to those 1425 of 1988 members of the European Association of Neurosurgical Societies (EANS) who agreed to participate in surveys to assess treatment strategies for withdrawal of tobacco smoking during aSAH. Factors contributing to physicians' posture towards NRT were assessed.
A total of 158 physicians from 50 nations participated in the survey (response rate 11.1%); 68.4% (108) were affiliated with university hospitals and 67.7% (107) practiced at high-volume neurovascular centers with at least 30 treated aSAH cases per year. Overall, 55.7% (88) of physicians offered NRT to smokers with aSAH, 22.1% (35) offered non-NRT support including non-nicotine medication and counselling, while the remaining 22.1% (35) did not actively support smoking cessation. When smoking was not possible, 42.4% (67) of physicians expected better clinical outcomes when prescribing NRT instead of nicotine deprivation, 36.1% (57) were uncertain, 13.9% (22) assumed unaffected outcomes, and 7.6% (12) assumed worse outcomes. Only 22.8% (36) physicians had access to a local smoking cessation team in their practice, of whom half expected better outcomes with NRT as compared to deprivation.
A small majority of the surveyed physicians of the EANS offered NRT to support smoking cessation in hospitalized patients with aSAH. However, less than half believed that NRT could positively impact clinical outcome as compared to deprivation. This survey demonstrated the lack of consensus regarding use of NRT for hospitalized smokers with aSAH.
Keywords
Humans, Nicotine/adverse effects, Smokers, Smoking Cessation, Subarachnoid Hemorrhage/complications, Subarachnoid Hemorrhage/drug therapy, Surveys and Questionnaires, Tobacco Use Cessation Devices, Cerebral aneurysm, Cerebrovascular disease, Intracranial aneurysm, Intracranial hemorrhage, Neurocritical care, Nicotine, Nicotine replacement products, SAH (subarachnoid hemorrhage), Smoking cessation agents, Stroke, Tobacco use cessation
Pubmed
Web of science
Open Access
Yes
Create date
27/09/2022 8:40
Last modification date
19/11/2022 7:11
Usage data